WO2006013261A2 - Utilisation de fibroblastes gingivaux en therapie cellulaire vasculaire. - Google Patents
Utilisation de fibroblastes gingivaux en therapie cellulaire vasculaire. Download PDFInfo
- Publication number
- WO2006013261A2 WO2006013261A2 PCT/FR2005/001690 FR2005001690W WO2006013261A2 WO 2006013261 A2 WO2006013261 A2 WO 2006013261A2 FR 2005001690 W FR2005001690 W FR 2005001690W WO 2006013261 A2 WO2006013261 A2 WO 2006013261A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmp9
- culture
- cultures
- fibroblasts
- cml
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to the use of gingival fibroblasts in vascular cell therapy, in particular for the treatment of arterial pathologies.
- the arterial wall consists of three superimposed layers, called tunics.
- the inner tunic (intima) consists of a layer of endothelial cells.
- the intermediate tunic (media) consists mainly of smooth muscle fibers and connective tissue rich in elastic fibers.
- the outer tunic (adventitia) is a conjunctive envelope that surrounds the whole arteries are subject to many assaults of various origins (hypoxia , lipid overload, hemodynamic forces, atheroma, hypertension, etc.), which can induce lesions of the arterial wall.
- an abnormal healing reaction can occur, resulting from an imbalance between the degradation and the synthesis of the extracellular matrix, and inducing a pathological arterial remodeling, which can result in a vascular enlargement (anev ⁇ sme) , or on the contrary by a const ⁇ ction (stenosis, occurring secondarily during the atherogenesis, or restenosis, consecutive in particular with an angioplasty evolving during the course of the cicatricial remodeling towards the reappearance of a stenosis).
- anev ⁇ sme vascular enlargement
- stenosis occurring secondarily during the atherogenesis, or restenosis, consecutive in particular with an angioplasty evolving during the course of the cicatricial remodeling towards the reappearance of a stenosis
- MMP9 Matrix metalloproteinase-9 synthesized by infiltrated leukocytes and physiological host cells (endothelial cells, smooth muscle cells and adventitious fibroblasts) and which is largely responsible for the fragmentation of elastic fibers (THOMPSON, J. Clin Invest. 96: 318-326, 1995).
- the rarefaction of the CMLs in the media causes a decrease in the synthesis of the components of the extracellular matrix, and that of the matrix protease inhibitors, which are mainly synthesized by these CMLs (LOPEZ-CANDALES et al., Am. Pathol., 150: 993-1007, 1997).
- retractile fibrous remodeling which can also be considered an abnormal healing process.
- This remodeling is characterized by intimal fibrous hyperplasia (LAFONT et al., Cire Res 76 (6): 996-1002, 1995), and appears to be related to an increase in collagen in the neointima, the media and the adventitia (LAFONT et al., Circulation 100 (10): 1109-1115, 1999; DURAND et al., Heart Evidence Arch., 94 (6): 605-611, 2001).
- the treatment of arterial diseases is mainly based on surgery and interventional cardiology (vascular surgery, aortocoronary and peripheral bypass grafting, dacron aortic prosthesis, coronary and peripheral arterial angioplasty, aortic stents, etc.).
- interventional cardiology vascular surgery, aortocoronary and peripheral bypass grafting, dacron aortic prosthesis, coronary and peripheral arterial angioplasty, aortic stents, etc.
- these invasive techniques do not treat the cause but the consequences of the pathology. They allow an improvement of the patient's situation without being able to stop the development of the disease.
- ALLAIRE et al. J. Clin Invest 102 (7): 1413-1420, 1998) observed, in an experimental model of aneurysm in the rat, that the local implantation of CMLs in the arterial wall induced inhibition of elastic fiber degradation and aneurysm formation. It has also been shown in rats that previously formed experimental aneurysms can be stabilized by local injection of CML. This stabilization is associated with a secretion of paracrine-derived TGF ⁇ at the level of cell transplantation (LOSY et al., J. Vase, Surg 37 (6): 1301-1309, 2003).
- CMLs are mesenchymal cells capable of migrating, adhering, and proliferating within the soft connective tissues of the gingiva, thus maintaining the integrity of the gingival tissue subjected to many aggressions such as mechanical forces, bacterial infections , variations in pH, temperature, etc.
- gingival fibroblasts are able to change phenotype, and respond to stimuli from the gingival tissue environment by proliferation, migration, synthesis or degradation of extracellular matrix components.
- collagens types I, III, V, VI, VII, XII
- elastic fibers proteoglycans and glycosaminoglycans, glycoproteins.
- proteoglycans and glycosaminoglycans, glycoproteins.
- enzymes especially metalloproteases
- tissue inhibitors of metalloproteases which inhibit the active forms of MMPs.
- the inventors performed co-cultures of gingival fibroblasts and of CMLs, and observed that the interactions between these cells led to the inhibition by the gingival fibroblasts of the MMP9 activity by the CML, as well as to the potentiation of the secretion of TGF ⁇ by the two cell types. These effects are specific for gingival fibroblasts, and are not observed when CMLs are co-cultured with dermal or adventitious fibroblasts.
- the gingival fibroblasts have on the one hand an inhibitory effect on one of the main factors of the formation of aneurysms, namely the MMP9 responsible for the degradation of the elastic network, and on the other hand an activating effect on a favorable factor for the stabilization of aneurysms, namely the secretion of TGF ⁇ .
- the inventors have also carried out, in the rabbit, in vivo tests for transplantation of gingival fibroblasts obtained from a gingival tissue sample from a rabbit, in the arterial wall of said rabbit, and found that these autologous gingival fibroblasts were able to fit into the wall, at the media level.
- the subject of the present invention is therefore the use of gingival fibroblasts for obtaining a cellular composition intended for the treatment of a pathology of the remodeling of a non-mineralized connective tissue other than the gingival tissue, in particular a pathology. arterial remodeling.
- the gingival fibroblasts can be used, in accordance with the invention, in all vascular pathologies, in particular arterial, with profound alterations of the extracellular matrix. These include: atherosclerosis, vulnerable plaque, restenosis, arterial aneurysms, aortic dissection. Outside the vascular domain, gingival fibroblasts may also modulate tissue remodeling in pathologies involving alterations of the extracellular matrix: skin scarring, tissue repair (burns, cancer, loss of substances).
- said pathology is aneurysm.
- said pathology is stenosis or restenosis after angioplasty.
- Said fibroblasts are preferably autologous fibroblasts, ie fibroblasts originating from gingival tissue previously taken from the subject for whom the treatment is intended, and cultured. Preferably these fibroblasts are cultured for at least 14 days, and advantageously for 14 to 70 days.
- Gingival fibroblast cultures that can be used for the implementation of the present invention can be obtained by conventional techniques, which are known per se to those skilled in the art (BARLOVATZ-MEIMON et al., "Animal cell culture” p. Paris: INSERM, 2003).
- fibroblasts in the arterial wall can be carried out in various ways; either locally by injection using balloon catheters equipped with micro-needles (INFILTRATOR) injection externally or internally into the adventitia or the tissue pediavascular, or by the general route (peripheral or arterial venous upstream of the site of injection with addressing carried out by magnetic guidance (prior intracellular incorporation of superparamagnetic nanoparticles), or biological (WILHEM et al., Eur. Biophys. J. 31 (2): 118-125, 2002; PANYAM et al., J. Drug Target 10 (6): 515-523, 2002).
- INFILTRATOR micro-needles
- Gingival fibroblasts are labeled with anionic nanoparticles of maghemite as described by WlLHEM et al. (Biomaterials 24: 1001-1011, 2003). Gingival fibroblasts (six different cultures) are grown to confluence in 10% fetal calf serum (FCS); and after 48 h, the culture supernatant is removed, and the cells are cultured in serum-free medium. The marking quality of gingival fibroblasts by these nanoparticles is controlled by Perl staining
- Co-cultures of labeled gingival fibroblasts (FG) and smooth muscle cells (CML) are made in collagen gels according to the method described by GILLERY et al. (Experientia 45 (1): 98-101, 1989).
- cells are obtained from gingival specimens for gingival fibroblasts, and from the arterial media for smooth muscle cells.
- the samples (gingiva and arterial media) are put in first culture in petri dishes in DMEM / SVF20% medium. At confluence, the cells are trypsinized and put back into culture in DMEM / SVF10% medium. After several passages in this medium, the cells are cultured in type I collagen (60,000 cells in 2 ml of collagen) for 3, 7, 14 or 21 days.
- the culture media (DMEM / SVF10%) in which the bathing gels are changed weekly.
- MMP9 secretion of MMP9 is localized by immunodetection on D3, and observed by light microscopy (xl60). MMP9 is not detected at the level of fibroblasts: it is detected only at the places corresponding to the location of the CML in the gel.
- A MMP2 activity for 600 unlabeled fibroblasts (control);
- B MMP2 activity for 600 labeled fibroblasts cultured Gel 'collagen
- C MMP2 and MMP9 activities for 600 CML grown in collagen gel
- Total RNA (1 or 2 ⁇ g) are extracted from cultures or co-cultures of FG and CML on day 14, using the MMP-CytoXpress Multiplex PCR Kit (BioSource International).
- the mRNAs obtained are retro-transcribed using a reverse transc ⁇ ptase, then a PCR is carried out using primers specific for MMP9 as follows: a denaturation step at 95 ° C. for 1 mm, 5 cycles of denaturation at 94 ° C. for 1 mm and hybridization at 60 ° C. for 4 mm, 35-40 denaturation cycles at 94 ° C. for 1 mm and hybridization at 68 ° C. for 2.5 mm, and a step final at 70 ° C.
- Molecular weight marker DNA A: non-labeled FG culture (1 ⁇ g RNA); B: culture of FG brands (1 ⁇ g RNA); C-culture of CML (1 ⁇ g RNA), D: co-culture CML and FG (1 ⁇ g RNA); E: co-culture CML and FG (2 ⁇ g RNA).
- the MMP9 inhibitor (TIMP-I) is expressed by gingival fibroblasts, and inhibits the active form of MMP9 by forming an inactive MMP9 / TIMP-1 complex.
- the cellular interactions are studied through the expression of TIMP-I at D3, D7, D14, D21 (days of culture). Evaluation of TIMP-I production by dot-blot
- the membranes are then incubated with an anti-TIMP-1 anti-human goat polyclonal primary antibody (1/500, R & D Systems, ref AF970) overnight at room temperature.
- the primary antibody is specific for free forms of TIMP-I.
- the blots are incubated with a secondary antibody labeled with peroxidase (1/1000), for 1 hour, then deposited in a revealing solution containing hydrogen peroxide and diacylhydrazide (Luminol, Boehringer, No.
- the image of the film is transmitted to a computer using a video camera.
- the software (Imagenia 3000, BIOCOM 200 station) evaluates on the one hand the density of the spots revealed on the membranes, and on the other hand their surface of a semi-automatic way by definition of the contour. The results are shown in Figure 4B.
- M molecular weight marker DNA
- A culture of unlabeled FG (1 ⁇ g RNA)
- B labeled FG culture (1 ⁇ g RNA)
- C culture of CML (1 ⁇ g RNA)
- D co-culture of CML and FG (1 ⁇ g RNA)
- E co-culture of CML and FG (2 ⁇ g RNA).
- the cellular interactions are studied through the production of the MMP9 / TIMP-1 complexes at D3, D7, D14, D21 (days of culture), by ELISA test using a kit.
- the cellular interactions are studied through the expression of the cytokine TGF ⁇ on D3, D7, D14, D21 / D28 (days of culture). Evaluation of TGF ⁇ production by ELISA test
- TGF ⁇ The production of TGF ⁇ was evaluated by test
- FG culture of 10 non-labeled FG
- FG * culture of 10 5 labeled FGs
- CML cultivation of 10 5 CML
- TGF ⁇ The production of TGF ⁇ was evaluated by dot-blot, using a monoclonal mouse anti-TGF ⁇ 1 antibody (R & D Systems, MAB ref.240), and using the protocol described above in the case of TIMP. -I.
- the dot-blot results at D3, D7, D14, D28 are shown in Figure 8.
- FG culture of 10 5 unmatched FGs
- CML cultivation of 10 5 CML
- CML / FG * co-culture of labeled 10 5 FG and 10 5 CML.
- Co-cultures of dermal fibroblasts (FD) or adventitious (FA) and smooth muscle cells (CML) are made in collagen gel, using the same protocol as that described in Example 1 above for gingival fibroblasts .
- the cells are obtained from skin samples for dermal fibroblasts, weed samples for adventitious fibroblasts, and from arterial media samples for smooth muscle cells.
- dermal or adventitic fibroblast cultures and smooth muscle cell cultures are performed separately under the same conditions.
- Recombinant MMP9 (R & D Systems, P / N 911-MP) are subject to same electrophoresis to control the type of MMP analyzed.
- B MMP2 activity for 600 FG grown in collagen gel
- C MMP2 activity for 600 FD grown in collagen gel
- Gingival fibroblasts such as dermal or adventitic fibroblasts, do not appear to modify the secretion of the
- the three-dimensional culture of arteries injured in collagen gel has been developed by the inventors to provide a model for the analysis of arterial remodeling over time. Obtaining crops
- Atherosclerotic lesions are induced in 5 New Zealand white rabbits by the combination of air drying and a high cholesterol diet, as described by LAFONT et al. (Wax. the
- the rabbits are sacrificed by intracardiac injection of phenobarbital.
- the arteries are collected after dissection, and stored in DMEM containing 20% FCS, at 40 ° C., for 3-10 hours, before culturing. In this way, 5 atherosclerotic arteries' progressive (AAP) and 5 atherosclerotic arteries 24 hours after angioplasty (AAA) are collected.
- AAP atherosclerotic arteries' progressive
- AAAA atherosclerotic arteries 24 hours after angioplasty
- each artery is rinsed with Hanks solution and dissected to preserve the weed and remove surrounding tissue. Finally, each artery is broken down into 4 segments of 5-7 mm. Each segment is placed in an Erlenmeyer flask
- the arteries and their collagen networks are recovered, rinsed with IX PBS, and fixed in a 4% PBS / paraformaldehyde solution for 48 hours. They are then dehydrated in alcohol 70 °, 95 ° then 100 °, and finally in toluene before inclusion in paraffin.
- the paraffin blocks are prepared for cutting.
- the culture supernatants of the 5 series of arteries are stored at -8O 0 C.
- Sirius red protocol After rehydration, the sections are covered with Sirius red for 30 min. The microscopic preparations are finally rinsed in distilled water before dehydration and final assembly.
- Catechin (+) -fuchsin protocol after partial rehydration (stopped with 95 ° alcohol), the sections are immersed in a coloring solution, protected from light, for 2 1/2 hours. A quick rinse with 95 ° alcohol (with 2 drops of hydrochloric acid) is carried out before dehydration and final assembly. Cell count
- the haemalun-eosin stained sections are observed under a microscope coupled to a computer (BIOCOM 200 station).
- Semi-automatic cell counting is made possible by pointing the nuclei. The results are given in number of cells per unit area.
- AAP intimal proliferations
- AAA neointima
- measurements of media thickness, intimal proliferation (AAP) and neointima (AAA) thickness measurements are performed.
- the measurements are taken 10-12 times, in 6 different zones inside each artery in culture.
- the software can evaluate the relative surface of the collagen component (on sections red-stained Sirius, observed in polarized light to highlight the fibrillar collagens).
- the components of the collagen network are evaluated in intimal proliferations (AAP) and neointima (AAA). In both cases, an increase in the density of the collagen network is observed over time. In addition, the measurements being performed on sections observed in polarized light, the observed increase concerns the fibrillar component of the collagen network.
- AAP intimal proliferations
- AAA neointima
- the software can evaluate the relative surface of the elastic networks (on catechin (+) -fuchsin stained sections).
- the relative area of the elastic network components in the media shows a reduction over time.
- the reduction is significant between D3 and D14 (p ⁇ 0.01) and very significant between d14 and d14.
- the haemalun-eosin stained sections are observed by UV electron microscopy. After photography of the sections and computer study of the photos, the length of the elastic fibers between two points of fragmentation is measured. This length reflects the state of fragmentation: the shorter the length of the fibers, the more fragmentation is significant.
- the set of morphometric analyzes shows the maintenance of arterial tissue coherence in culture until the end of the experimentation period.
- dynamic phenomena of cellular and matrix remodeling observed in vitro correspond to data established in vivo, in both violent inflammatory (A ⁇ A) and slow (AAP) situations. It thus appears that organotypic cultures of arteries damaged by collagen gel constitute a model of valid ex vivo aneurysm.
- EXAMPLE 4 EVALUATION OF THE SECRETION OF KEY ENZYMES OF ARTERIAL REMODELING BY ORGANOTYPIC CULTURES OF ARTERIES DISENGAGED
- the expression of secreted MMP1, MMP2, MMP3, TIMP-I and TIMP-2 in the organotypic culture medium of AAA and AAP arteries is analyzed by dot-blot as described in Example 1 above, at the same time. using human antibodies against these MMPs and TIMPs (Valbiotech). As a control, the presence of these MMPs and TIMPs is also sought in the culture serum (FCS).
- FCS culture serum
- MMP-I A
- MMP-3 B
- MMP1 and MMP3 are absent from cultured serum
- C an increase in the expression of MMP2 (C) during the first week (D7) and a decrease during the second week (D14), then a new increase which reaches its maximum at D28.
- AAA angioplasty
- concentrations in MMP2 are very significantly lower in serum than in culture supernatants;
- TIMP-I a gradual increase in the expression of TIMP-I (D) during the first two weeks, with no significant difference between the two sets of arterial cultures.
- AAA cultures show a peak of TIMP-I, while expression of the enzyme stagnates within AAP cultures.
- TIMP-I is absent from cultured serum; an increase in the expression of TIMP-2 (E) the first week before stagnation at levels much lower inside the AAP cultures.
- E an increase in the expression of TIMP-2
- TIMP-2 After angioplasty, a peak of TIMP-2 expression is also observed the first week before stagnation at very high concentrations.
- TIMP-2 remains largely more expressed after angioplasty than in AAP cultures. TIMP-2 is absent from cultured serum.
- MMP2 and MMP9 secreted in the organotypic culture medium of AAA and AAP arteries.
- 70 ⁇ l of arterial organotypic culture supernatant (AAP and AAA) are diluted 3/5 in 1 M Tris pH 6.8 containing 50% glycerol and 0.4% bromophenol blue and then subjected to electrophoresis 10% SDS polyacrylamide gel containing 1 mg / ml of porcine skin gelatin (Sigma, ref G2500) in a Laemmli buffer solution, at 40 ° C., at 80 volts in the concentration gel, then 180 volts in the separation gel. After migration, the gels are washed in 2.5% Triton X-100 (2 x 30 min at room temperature) and then incubated in saline buffer solution at 37 ° C for 48 hours.
- Tris pH 6.8 containing 50% glycerol and 0.4% bromophenol blue
- SDS polyacrylamide gel containing 1 mg / ml of porcine skin gelatin (Sigma, ref G2500) in a Laemmli buffer solution, at 40 ° C., at
- the gels are then stained with 0.25% Coomassie blue (Biorad, ref R250) and then discolored; the enzymatic activity bands appear translucent, as shown in Figure 11.
- the computerized morphometry analysis makes it possible to quantify the gelatinolytic activities revealed by the zymography.
- the image of the gel is transmitted to the computer using a video camera.
- the software (Imagenia 3000, BIOCOM 200 station) transforms the intensity of the enzymatic bands into gray level: the higher the intensity of the band, the higher the gray level.
- the absence of lysis corresponds to the gray level 0
- the maximum lysis corresponds to the gray level 255.
- the band surface is measured in a semi-automatic manner by definition of the contour.
- the quantification, in arbitrary unit U is obtained by the product of the surface S of the band and the level of gray.
- the dot-blot is performed as described in Example 1 above, using a human antibody directed against MMP9 (Valbiotech). As a control, the presence of MMP9 is also sought in the culture serum (FCS). The results are shown in Figure 12.
- the IL-1 ⁇ , IL-4, IL-6, and TGF ⁇ cytokines are quantified in the J3, J1, J14 and J28 artery culture supernatant by ELISA as described in Example 1 above, using respectively Quantikine ⁇ kits (R & D Systems, ref. DLB50), DuoSet® ELISA Development (R & D Systems, DY204, DY206 and DY240). The average values obtained are transferred in the form of histograms and analyzed statistically. The results are shown in Figure 13.
- C quantification of IL-4
- D quantification of TGF ⁇
- the blocking solution is removed and replaced with a primary antibody diluted in a solution containing 1% BSA and PBS-Tween 0.05%: 1/50 anti-MMP3 or anti-MMP9 [Oncogene (Merk Eurolab)].
- the sections are covered with the primary antibody overnight at room temperature.
- the microscopic preparations are rinsed 3x10 min in PBS IX.
- the sections are then covered with a specific biotinylated secondary antibody for 90 min (Vector Vestatain Kit 11 (ABC kit) Biovalley, Elite PK-6102).
- the microscopic preparations are rinsed 3x in PBS IX. Endogenous peroxidases are blocked by the addition of hydrogen peroxide on the sections for 20 minutes at 37 ° C.
- the microscopic preparations are rinsed twice in IX PBS and once in 3% PBS-NaCl.
- the avidin-biotin complex is prepared and deposited on the sections for 45 min at room temperature.
- the microscopic preparations are rinsed twice in 3% PBS-NaCl and then in 0.1M Tris-HCl, pH 7.6.
- the dispersion of MMP9 appears intensely along the inner elastic lamina on day 3 before migrating into the mean area of the neointima, and finally spreads diffusely within all the media.
- the distribution of MMP3 has a clearly more moderate kinetics: at J3, its presence is still diffused in the media, and it is only at J7 that the dispersion of MMP3 accumulates along the inner elastic lamina, before migrating into the average area of the neointima to D14, and to extend to all neointima to D28.
- the marking of MMP3 remains less intense than that of MMP9.
- A cell culture of 100,000 FG in collagen gel
- A organotypic culture of collagen gel arteries A / FG ⁇ co-culture of arteries and 100,000 collagen gel gingival fibroblasts.
- Ordinate secretion of MMP9 (in pg).
- a large increase in the secretion of TIMP-I is observed in the A / FG co-cultures compared to that detected in the separate cultures FG and A ( Figure 16). The same results are obtained on D3, D7, D14 and D21.
- MMP9 and TIMP-I mRNAs were extracted from co-cultures of gingival arteries and fibroblasts at day 14, and RT PCR analysis, were performed as described in Example 1 above, at using primers specific for MMP9 and TIMP-I.
- the results of transcriptional analysis of MMP9 and TIMP-I are shown in Figures 17 and 18, respectively.
- S DNA molecular weight standard (Multiplex PCR kit ⁇ , BioSource International); G: collagen gel alone; FG: cell culture of FG (1 ⁇ g RNA);
- A organotypic culture of arteries (1 ⁇ g RNA);
- a / FG co-culture of arteries and FG (1 ⁇ g RNA).
- A organotypic culture of collagen gel arteries
- the results show that the amount of MMP9 / TIMP-1 complexes is increased in co-cultures of arteries and FG (x 1.8).
- the objective of this study is to determine the feasibility of injection and validation of fibroblast labeling by nanoparticles verified by Perl's staining. Human cells injected into rabbits the
- the human gingival fibroblasts are labeled in monolayer culture by ferro ⁇ magnetic nanoparticles, as described in Example 1 above and then trypsimed.
- A model of normal arteries (x10 and x40)
- B model of aneurysm (x5)
- FIG. 21A The results show that there is a superposition of HLA anti-human staining and Perl's staining (FIG. 21A) which confirms the validity of this injection technique.
- the cells have a normal morphology, and one can observe an INFILTRATOR penetration site in the artery (see arrow Figure 21A, x40).
- Figure 21B shows an injection of fibroblasts into an aneurysmal artery.
- the gingival fibroblasts are labeled in monolayer culture by ferro-magnetic nanoparticles, as described in Example 1 above and then trypsimed.
- Perl makes it possible to see the nanoparticles on the histological sections of 6 ⁇ m.
- the injected fibroblasts are located in the media, and have a normal morphology.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007519832A JP4891903B2 (ja) | 2004-07-02 | 2005-07-01 | 血管細胞治療のための歯肉繊維芽細胞の使用 |
EP05786212A EP1773420B1 (fr) | 2004-07-02 | 2005-07-01 | Utilisation de fibroblastes gingivaux en therapie cellulaire vasculaire. |
DK05786212.0T DK1773420T3 (da) | 2004-07-02 | 2005-07-01 | Anvendelse af gingivale fibroblaster til vaskulær celleterapi |
US11/571,542 US8119122B2 (en) | 2004-07-02 | 2005-07-01 | Use of gingival fibroblasts for vascular cell therapy |
CA2572554A CA2572554C (fr) | 2004-07-02 | 2005-07-01 | Utilisation de fibroblastes gingivaux en therapie cellulaire vasculaire |
AT05786212T ATE480265T1 (de) | 2004-07-02 | 2005-07-01 | Verwendung von zahnfleischfibroblasten zur behandlung von vaskulären zellen |
DE602005023468T DE602005023468D1 (de) | 2004-07-02 | 2005-07-01 | Verwendung von zahnfleischfibroblasten zur behandlung von vaskulären zellen |
AU2005268746A AU2005268746B2 (en) | 2004-07-02 | 2005-07-01 | Use of gingival fibroblasts for vascular cell therapy |
US13/345,624 US8609085B2 (en) | 2004-07-02 | 2012-01-06 | Use of gingival fibroblasts for vascular cell therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0407357 | 2004-07-02 | ||
FR0407357A FR2872431B1 (fr) | 2004-07-02 | 2004-07-02 | Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/571,542 A-371-Of-International US8119122B2 (en) | 2004-07-02 | 2005-07-01 | Use of gingival fibroblasts for vascular cell therapy |
US13/345,624 Continuation US8609085B2 (en) | 2004-07-02 | 2012-01-06 | Use of gingival fibroblasts for vascular cell therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006013261A2 true WO2006013261A2 (fr) | 2006-02-09 |
WO2006013261A3 WO2006013261A3 (fr) | 2006-06-15 |
Family
ID=34946541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/001690 WO2006013261A2 (fr) | 2004-07-02 | 2005-07-01 | Utilisation de fibroblastes gingivaux en therapie cellulaire vasculaire. |
Country Status (11)
Country | Link |
---|---|
US (2) | US8119122B2 (fr) |
EP (1) | EP1773420B1 (fr) |
JP (1) | JP4891903B2 (fr) |
AT (1) | ATE480265T1 (fr) |
AU (1) | AU2005268746B2 (fr) |
CA (1) | CA2572554C (fr) |
DE (1) | DE602005023468D1 (fr) |
DK (1) | DK1773420T3 (fr) |
ES (1) | ES2354220T3 (fr) |
FR (1) | FR2872431B1 (fr) |
WO (1) | WO2006013261A2 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1972685A1 (fr) | 2007-03-20 | 2008-09-24 | Universite Rene Descartes (Paris V) | Milieu de culture pour fibroblastes de gencives |
WO2009047300A2 (fr) * | 2007-10-09 | 2009-04-16 | Universite Rene Descartes - Paris V | Dispositif pour l'administration de cellules et procédé de thérapie cellulaire utilisant ledit dispositif |
WO2010100282A1 (fr) * | 2009-03-06 | 2010-09-10 | Universite Paris Descartes | Procédé de traitement du cancer |
WO2011012575A1 (fr) | 2009-07-27 | 2011-02-03 | Scarcell Therapeutics | Dispositif de cathéter à ballonnet |
US8303948B2 (en) * | 2006-08-10 | 2012-11-06 | Universite Paris Descartes | Method for treating skin wounds |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009231396B2 (en) * | 2008-03-31 | 2015-05-07 | Scarcell Therapeutics | Method for the cosmetic treatment of skin ageing |
FR3008316B1 (fr) * | 2013-07-09 | 2020-01-31 | Assistance Publique - Hopitaux De Paris | Utilisation de fibroblastes gingivaux dans le traitement de l'alopecie |
WO2017188403A1 (fr) * | 2016-04-27 | 2017-11-02 | ロート製薬株式会社 | Cellule souche mésenchymateuse exprimant au moins un marqueur de surface cellulaire choisi dans le groupe constitué par cd201, cd46, cd56, cd147 et cd165 et procédé pour sa préparation, composition pharmaceutique contenant la cellule souche mésenchymateuse et procédé pour sa préparation |
EP3541399A1 (fr) * | 2016-11-18 | 2019-09-25 | Scarcell Therapeutics | Compositions utiles pour le traitement de maladies liées à l'immunité |
SG11202105105SA (en) * | 2018-11-30 | 2021-06-29 | Shiseido Co Ltd | Composition for treating or preventing skin pigmentation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0393788A2 (fr) * | 1989-04-17 | 1990-10-24 | Koken Co. Ltd. | Prothèse vasculaire et procédé de production pour prothèse vasculaire |
WO1998022154A2 (fr) * | 1996-11-21 | 1998-05-28 | Tissue Engineering, Inc. | Mousses de biopolymere pour la reparation et la reconstruction de tissus |
US5885829A (en) * | 1996-05-28 | 1999-03-23 | The Regents Of The University Of Michigan | Engineering oral tissues |
WO1999051164A1 (fr) * | 1998-04-03 | 1999-10-14 | Reprogenesis, Inc. | Dispositif de reconstruction des tissus mous et son procede d'utilisation |
WO2001082773A2 (fr) * | 2000-04-28 | 2001-11-08 | The Regents Of The University Of California | Structures utiles dans le genie osseux et procedes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040101959A1 (en) * | 2002-11-21 | 2004-05-27 | Olga Marko | Treatment of tissue with undifferentiated mesenchymal cells |
-
2004
- 2004-07-02 FR FR0407357A patent/FR2872431B1/fr not_active Expired - Fee Related
-
2005
- 2005-07-01 DK DK05786212.0T patent/DK1773420T3/da active
- 2005-07-01 DE DE602005023468T patent/DE602005023468D1/de active Active
- 2005-07-01 JP JP2007519832A patent/JP4891903B2/ja active Active
- 2005-07-01 EP EP05786212A patent/EP1773420B1/fr active Active
- 2005-07-01 CA CA2572554A patent/CA2572554C/fr active Active
- 2005-07-01 US US11/571,542 patent/US8119122B2/en active Active
- 2005-07-01 AU AU2005268746A patent/AU2005268746B2/en active Active
- 2005-07-01 WO PCT/FR2005/001690 patent/WO2006013261A2/fr active Application Filing
- 2005-07-01 AT AT05786212T patent/ATE480265T1/de not_active IP Right Cessation
- 2005-07-01 ES ES05786212T patent/ES2354220T3/es active Active
-
2012
- 2012-01-06 US US13/345,624 patent/US8609085B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0393788A2 (fr) * | 1989-04-17 | 1990-10-24 | Koken Co. Ltd. | Prothèse vasculaire et procédé de production pour prothèse vasculaire |
US5885829A (en) * | 1996-05-28 | 1999-03-23 | The Regents Of The University Of Michigan | Engineering oral tissues |
WO1998022154A2 (fr) * | 1996-11-21 | 1998-05-28 | Tissue Engineering, Inc. | Mousses de biopolymere pour la reparation et la reconstruction de tissus |
WO1999051164A1 (fr) * | 1998-04-03 | 1999-10-14 | Reprogenesis, Inc. | Dispositif de reconstruction des tissus mous et son procede d'utilisation |
WO2001082773A2 (fr) * | 2000-04-28 | 2001-11-08 | The Regents Of The University Of California | Structures utiles dans le genie osseux et procedes |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8303948B2 (en) * | 2006-08-10 | 2012-11-06 | Universite Paris Descartes | Method for treating skin wounds |
EP1972685A1 (fr) | 2007-03-20 | 2008-09-24 | Universite Rene Descartes (Paris V) | Milieu de culture pour fibroblastes de gencives |
WO2009047300A2 (fr) * | 2007-10-09 | 2009-04-16 | Universite Rene Descartes - Paris V | Dispositif pour l'administration de cellules et procédé de thérapie cellulaire utilisant ledit dispositif |
WO2009047300A3 (fr) * | 2007-10-09 | 2009-07-02 | Univ Paris Descartes | Dispositif pour l'administration de cellules et procédé de thérapie cellulaire utilisant ledit dispositif |
JP2011512167A (ja) * | 2007-10-09 | 2011-04-21 | ユニヴェルシテ・ルネ・デカルト・パリ・サンク | 細胞を投与するデバイス及び上記デバイスを用いた細胞治療法 |
WO2010100282A1 (fr) * | 2009-03-06 | 2010-09-10 | Universite Paris Descartes | Procédé de traitement du cancer |
WO2011012575A1 (fr) | 2009-07-27 | 2011-02-03 | Scarcell Therapeutics | Dispositif de cathéter à ballonnet |
Also Published As
Publication number | Publication date |
---|---|
US8609085B2 (en) | 2013-12-17 |
EP1773420A2 (fr) | 2007-04-18 |
JP2008505164A (ja) | 2008-02-21 |
US20080025954A1 (en) | 2008-01-31 |
DE602005023468D1 (de) | 2010-10-21 |
AU2005268746B2 (en) | 2011-01-06 |
CA2572554A1 (fr) | 2006-02-09 |
ES2354220T3 (es) | 2011-03-11 |
WO2006013261A3 (fr) | 2006-06-15 |
FR2872431A1 (fr) | 2006-01-06 |
EP1773420B1 (fr) | 2010-09-08 |
FR2872431B1 (fr) | 2007-07-20 |
DK1773420T3 (da) | 2011-01-10 |
AU2005268746A1 (en) | 2006-02-09 |
JP4891903B2 (ja) | 2012-03-07 |
US8119122B2 (en) | 2012-02-21 |
US20120177613A1 (en) | 2012-07-12 |
ATE480265T1 (de) | 2010-09-15 |
CA2572554C (fr) | 2013-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1773420B1 (fr) | Utilisation de fibroblastes gingivaux en therapie cellulaire vasculaire. | |
Ni et al. | Exosomes derived from TIMP2-modified human umbilical cord mesenchymal stem cells enhance the repair effect in rat model with myocardial infarction possibly by the Akt/Sfrp2 pathway | |
Polyakova et al. | Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles | |
Riau et al. | Preservation, sterilization and de-epithelialization of human amniotic membrane for use in ocular surface reconstruction | |
Guo et al. | The healing of full-thickness burns treated by using plasmid DNA encoding VEGF-165 activated collagen–chitosan dermal equivalents | |
Parat | The biology of caveolae: achievements and perspectives | |
Kanematsu et al. | Induction of smooth muscle cell-like phenotype in marrow-derived cells among regenerating urinary bladder smooth muscle cells | |
Bai et al. | Endothelial damage and stem cell repair in atherosclerosis | |
Longchamp et al. | The use of external mesh reinforcement to reduce intimal hyperplasia and preserve the structure of human saphenous veins | |
Ollitrault et al. | BMP-2, hypoxia, and COL1A1/HtrA1 siRNAs favor neo-cartilage hyaline matrix formation in chondrocytes | |
JP2006124389A (ja) | 間葉系幹細胞の遊離または増殖、および創傷治癒または創傷治癒促進のためのサブスタンスpの使用 | |
KR20150068425A (ko) | 신경 재생용 조성물, 구조물 및 방법 | |
Hsiao et al. | The impact of compositional topography of amniotic membrane scaffold on tissue morphogenesis of salivary gland | |
Yu et al. | Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression | |
Wang et al. | Rat model of chronic tympanic membrane perforation: a longitudinal histological evaluation of underlying mechanisms | |
CA2863472C (fr) | Peptide bifonctionnel | |
Pascual et al. | Host tissue response by the expression of collagen to cyanoacrylate adhesives used in implant fixation for abdominal hernia repair | |
Ballester-Servera et al. | Lysyl oxidase-dependent extracellular matrix crosslinking modulates calcification in atherosclerosis and aortic valve disease | |
Ji et al. | Comparing the characteristics of amniotic membrane-, endometrium-, and urinary-derived ECMs and their effects on endometrial regeneration in a rat uterine injury model | |
US20220213441A1 (en) | Extracellular matrix material and uses thereof | |
Wang et al. | Postconditioning attenuates coronary perivascular and interstitial fibrosis through modulating angiotensin II receptors and angiotensin-converting enzyme 2 after myocardial infarction | |
Sylakowski | Therapeutic Strategies of Matricellular Proteins in Cutaneous Wound Healing: Countervailing Chronic Wounds and Excessive Scarring. | |
van Haaften et al. | Human in vitro model of material-driven vascular regeneration reveals how cyclic stretch and shear stress differentially modulate inflammation and tissue formation | |
Factor et al. | 12th Biennial Meeting Abstracts Regeneration, Remodeling, and Repair: Mechanisms, Models, and Therapies for Heart and Vascular | |
FR3135267A1 (fr) | Nouvel actif de cicatrisation et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007519832 Country of ref document: JP Ref document number: 2572554 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005268746 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005786212 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005268746 Country of ref document: AU Date of ref document: 20050701 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005268746 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005786212 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11571542 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11571542 Country of ref document: US |